AG Mednet CEO Challenges Clinical Trial Industry Assumptions at Disruptive Innovations Conference
Pharmaceutical companies and clinical trial experts will gather in Boston to reinvent the clinical trial process
Online PR News – 10-September-2012 – Boston, MA – Is a zero-delay clinical trial possible? AG Mednet CEO Abraham Gutman thinks so.
Conducting an imaging trial is time-sensitive, expensive and risky. Just one submission error can cost up to seven weeks of trial delay, cost millions of sponsor dollars, and result in the potential loss of patient data. Simply speeding up the system only creates worse results, faster.
Those in attendance will debate whether:
• The current clinical trial system ready for truly disruptive changes that challenge the status quo
Who: AG Mednet CEO Abraham Gutman
What: During the 2nd Annual Disruptive Innovations to Advance Clinical Trials conference, designed for innovative drug development thinkers who are determined to reinvent clinical trials, Gutman will challenge the industry to strive for zero-delay, addressing the current state of the clinical trial ecosystem, common industry misconceptions and the potentially hazardous consequences associated with common assertions.
When: Thursday, September 13th at 4:00 pm
Where: The Fairmont Copley Plaza, Boston, MA
To arrange an interview with Gutman prior to or at the Dpharm conference, please call 781-893-0053 or email email@example.com. For more information about AG Mednet, please visit http://www.agmednet.com/zerodelay/.
About AG Mednet
Copyright 2015 Online PR Media | PO Box 5043 | La Quinta, CA 92248